Unlike CRISPR-Cas9, which creates double-strand breaks and relies on error-prone cellular repair, Brec1 performs a concerted "cut and paste" action that is inherently error-free.
The core of Hamburg’s research is , developed through directed molecular evolution by teams led by Prof. Joachim Hauber. Preclinical data showed the enzyme has no measurable
Preclinical data showed the enzyme has no measurable cytotoxic or genotoxic side effects, making it a viable candidate for human testing. 3. 2022 Milestones: The Hamburg Therapy Hub this latent reservoir reactivates
In 2022, Hamburg emerged as a primary hub for curative HIV research following significant investment in , a biotech startup utilizing "designer recombinase" technology. Unlike traditional antiretroviral therapy (ART) which only suppresses viral replication, the Brec1 recombinase acts as a molecular scalpel to precisely excise integrated HIV-1 DNA from the host genome. This paper details the 2022 expansion of Hamburg’s "Therapy Hub," the underlying Brec1 technology, and the transition toward Phase Ib/IIa clinical trials. 1. The Challenge: Beyond Viral Suppression " the underlying Brec1 technology
While modern ART allows people living with HIV (PLWH) to lead near-normal lives, it cannot eliminate the "provirus"—the viral DNA that integrates into the host's own genome. If ART is stopped, this latent reservoir reactivates, leading to viral rebound. A permanent cure requires the physical removal or permanent silencing of this integrated DNA.
Building upon the research conducted by and the University Medical Center Hamburg-Eppendorf (UKE) , this paper outlines the scientific and strategic progress made toward a functional HIV cure as of late 2022. Abstract